Author

D. Cescon

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Approach:statistical model· 2 Assay:ATAC-seq· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

M. Lupien· 2 shared S. J. Done· 2 shared A. Fortier· 1 shared B. H. Kains· 1 shared C. H. Arrowsmith· 1 shared E. L. Fernandes· 1 shared G. Deblois· 1 shared H. Kuasne· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

M. Lupien

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Non-coding mutations reveal cancer driver cistromes in luminal breast cancer

S. El Ghamrasni, R. Quevedo, J. R. Hawley, P. Mazrooei, Y. Hanna, I. Cirlan, H. Zhu, J. P. Bruce, L. E. Oldfield, S. Y. C. Yang, P. Guilhamon, J. Reimand, D. Cescon, S. J. Done, M. Lupien, T. Pugh

The paper identifies cancer driver cistromes in luminal breast cancer by analyzing non-coding mutations in cis-regulatory elements from ATAC-seq data and integrating them with somatic mutations.

bioRxiv · May 29, 2021Cancer Biology

GLUT1 inhibition blocks growth of RB1-positive Triple Negative Breast Cancer

Q. Wu, W. Alawi, G. Deblois, J. Cruickshank, S. Duan, E. L. Fernandes, J. Haight, S. A. Tonekaboni, A. Fortier, H. Kuasne, T. McKee, H. Mahmoud, S. Cameron, N. D. Artun, W. Chen, , C. H. Arrowsmith

This study shows that GLUT1 inhibition reduces growth of RB1-positive TNBC cells with high glycolytic activity and low OXPHOS, suggesting a therapeutic target in this subset.

bioRxiv · Sep 11, 2019Cancer Biology